ValiRx PLC (LSE:VAL) has progressed its strategic evolution into an agile life science incubator and translational drug discovery business focused on oncology and women's health. The company identifies early-stage, scientifically novel academic compounds and conducts rigorous preclinical testing to advance them toward commercial out-licensing. …
Venture Life Group plc (LSE:VLG) has maintained consistent operational focus on expanding international commercial distribution for its proprietary consumer self-care and dermatological products. The Berkshire-based consumer healthcare company develops, manufactures, and commercialises consumer self-care formulations. Its diversified commercial portfolio spans Oral Care (Dentyl), Women's …
Proteome Sciences plc (LSE:PRM) has advanced its leadership in quantitative protein analysis by expanding commercial adoption of its proprietary Tandem Mass Tag (TMT) technology. The life sciences company specializes in contract biomarker services and reagent manufacturing. Its patented TMT and TMTpro chemical tags allow …
PureTech Health PLC (LSE:PRTC) has continued to validate its unique hub-and-spoke biotherapeutic development and commercialisation model across global life-sciences markets. The company creates, develops, and commercialises novel therapies targeting severe central nervous system, autoimmune, and metabolic disorders. The company's operating architecture combines a wholly …
Provexis plc (LSE:PXS) has made significant operational progress in scaling the international commercial footprint of Fruitflow®, its patented, natural cardiovascular functional food ingredient. The life sciences company specializes in heart health ingredients. Extracted from water-soluble tomato concentrate, Fruitflow is scientifically proven and clinically validated …
RUA Life Sciences plc (LSE:RUA) has continued to advance the commercialisation of its proprietary biopolymer technologies and implantable cardiovascular devices across international medical markets. The Ayrshire-headquartered medical device group owns the intellectual property rights to Elast-Eon™, an innovative biostable polyurethane elastomer. Elast-Eon combines the …
SkinBioTherapeutics plc (LSE:SBTX) has continued the commercial rollout of its proprietary human microbiome platform while expanding clinical validation across diverse dermatological conditions. The life sciences company harnesses the therapeutic properties of beneficial skin bacteria to protect, repair, and enhance the human epidermal barrier. The …
Scancell Holdings plc (LSE:SCLP) has continued to advance its pioneering portfolio of therapeutic cancer vaccines and monoclonal antibodies engineered to harness the human immune system against advanced solid tumours. The clinical-stage biopharmaceutical company utilizes two proprietary technological platforms: ImmunoBody® and Moditope®. These platforms stimulate …
Smith & Nephew plc (LSE:SN.) has reinforced its operational turnaround strategy across global healthcare markets by accelerating the commercial integration of robotics, digital surgery platforms, and advanced implants. The multinational healthcare leader operates across three core business franchises: Orthopaedics, Sports Medicine & ENT, and …
Shield Therapeutics Plc (LSE:STX) has focused its corporate execution on expanding US prescription volumes for its proprietary oral iron therapy, Accrufer (ferric maltol). The commercial-stage pharmaceutical enterprise addresses the widespread medical challenge of iron deficiency and iron deficiency anaemia. While traditional oral iron salts …